These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33515704)

  • 61. O-GlcNAcylation: roles and potential therapeutic target for bone pathophysiology.
    Yan X; Zheng J; Ren W; Li S; Yang S; Zhi K; Gao L
    Cell Commun Signal; 2024 May; 22(1):279. PubMed ID: 38773637
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hyper-O-GlcNAcylation inhibits the induction of heat shock protein 70 (Hsp 70) by sodium arsenite in HeLa cells.
    Miura Y; Sato T; Sakurai Y; Sakai R; Hiraoka W; Endo T
    Biol Pharm Bull; 2014; 37(8):1308-14. PubMed ID: 25087952
    [TBL] [Abstract][Full Text] [Related]  

  • 63. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation.
    Dorfmueller HC; Borodkin VS; Schimpl M; van Aalten DM
    Biochem J; 2009 May; 420(2):221-7. PubMed ID: 19275764
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure.
    Lunde IG; Aronsen JM; Kvaløy H; Qvigstad E; Sjaastad I; Tønnessen T; Christensen G; Grønning-Wang LM; Carlson CR
    Physiol Genomics; 2012 Feb; 44(2):162-72. PubMed ID: 22128088
    [TBL] [Abstract][Full Text] [Related]  

  • 65. O-Linked N-Acetylglucosamine (O-GlcNAc) Transferase and O-GlcNAcase Interact with Mi2β Protein at the Aγ-Globin Promoter.
    Zhang Z; Costa FC; Tan EP; Bushue N; DiTacchio L; Costello CE; McComb ME; Whelan SA; Peterson KR; Slawson C
    J Biol Chem; 2016 Jul; 291(30):15628-40. PubMed ID: 27231347
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Versatile O-GlcNAc transferase assay for high-throughput identification of enzyme variants, substrates, and inhibitors.
    Kim EJ; Abramowitz LK; Bond MR; Love DC; Kang DW; Leucke HF; Kang DW; Ahn JS; Hanover JA
    Bioconjug Chem; 2014 Jun; 25(6):1025-30. PubMed ID: 24866374
    [TBL] [Abstract][Full Text] [Related]  

  • 67. O-GlcNAcylation and its role in the immune system.
    Chang YH; Weng CL; Lin KI
    J Biomed Sci; 2020 Apr; 27(1):57. PubMed ID: 32349769
    [TBL] [Abstract][Full Text] [Related]  

  • 68. OGT and OGA expression in postmenopausal skeletal muscle associates with hormone replacement therapy and muscle cross-sectional area.
    Toivonen MH; Pöllänen E; Ahtiainen M; Suominen H; Taaffe DR; Cheng S; Takala T; Kujala UM; Tammi MI; Sipilä S; Kovanen V
    Exp Gerontol; 2013 Dec; 48(12):1501-4. PubMed ID: 24365779
    [TBL] [Abstract][Full Text] [Related]  

  • 69. O-GlcNAc transferase inhibitors: current tools and future challenges.
    Trapannone R; Rafie K; van Aalten DM
    Biochem Soc Trans; 2016 Feb; 44(1):88-93. PubMed ID: 26862193
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Site-specific interplay between O-GlcNAcylation and phosphorylation in cellular regulation.
    Hu P; Shimoji S; Hart GW
    FEBS Lett; 2010 Jun; 584(12):2526-38. PubMed ID: 20417205
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of Global
    Sherazi AA; Jariwala KA; Cybulski AN; Lewis JW; Karagiannis J; Cumming RC; Timoshenko AV
    Anticancer Res; 2018 Dec; 38(12):6691-6697. PubMed ID: 30504378
    [TBL] [Abstract][Full Text] [Related]  

  • 72. E2f1 deletion attenuates infarct-induced ventricular remodeling without affecting O-GlcNAcylation.
    Dassanayaka S; Brittian KR; Jurkovic A; Higgins LA; Audam TN; Long BW; Harrison LT; Militello G; Riggs DW; Chitre MG; Uchida S; Muthusamy S; Gumpert AM; Jones SP
    Basic Res Cardiol; 2019 May; 114(4):28. PubMed ID: 31152247
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer.
    Phueaouan T; Chaiyawat P; Netsirisawan P; Chokchaichamnankit D; Punyarit P; Srisomsap C; Svasti J; Champattanachai V
    Oncol Rep; 2013 Dec; 30(6):2929-36. PubMed ID: 24126823
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Elevated expression of O-GlcNAc-modified proteins and O-GlcNAc transferase in corneas of diabetic Goto-Kakizaki rats.
    Akimoto Y; Kawakami H; Yamamoto K; Munetomo E; Hida T; Hirano H
    Invest Ophthalmol Vis Sci; 2003 Sep; 44(9):3802-9. PubMed ID: 12939295
    [TBL] [Abstract][Full Text] [Related]  

  • 75. O-GlcNAc cycling: implications for neurodegenerative disorders.
    Lazarus BD; Love DC; Hanover JA
    Int J Biochem Cell Biol; 2009 Nov; 41(11):2134-46. PubMed ID: 19782947
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Protein O-GlcNAcylation: emerging mechanisms and functions.
    Yang X; Qian K
    Nat Rev Mol Cell Biol; 2017 Jul; 18(7):452-465. PubMed ID: 28488703
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pregnancy decreases O-GlcNAc-modified proteins in systemic arteries of normotensive and spontaneously hypertensive rats.
    Troiano JA; Potje SR; Graton ME; Silva DS; da Costa RM; Tostes RC; Antoniali C
    Life Sci; 2021 Feb; 266():118885. PubMed ID: 33316265
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Regulation of Dauer formation by O-GlcNAcylation in Caenorhabditis elegans.
    Lee J; Kim KY; Lee J; Paik YK
    J Biol Chem; 2010 Jan; 285(5):2930-9. PubMed ID: 19940149
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy.
    Yokoe S; Asahi M; Takeda T; Otsu K; Taniguchi N; Miyoshi E; Suzuki K
    Glycobiology; 2010 Oct; 20(10):1217-26. PubMed ID: 20484118
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Analytical and Biochemical Perspectives of Protein O-GlcNAcylation.
    Ma J; Wu C; Hart GW
    Chem Rev; 2021 Feb; 121(3):1513-1581. PubMed ID: 33416322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.